tradingkey.logo
tradingkey.logo
Search

Medpace Holdings Inc

MEDP
Add to Watchlist
417.290USD
-6.710-1.58%
Close 05/11, 16:00ETQuotes delayed by 15 min
11.89BMarket Cap
25.72P/E TTM

Medpace Holdings Inc

417.290
-6.710-1.58%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.58%

5 Days

+0.06%

1 Month

-15.45%

6 Months

-30.77%

Year to Date

-25.70%

1 Year

+40.96%

TradingKey Stock Score of Medpace Holdings Inc

Currency: USD Updated: 2026-05-08

Key Insights

Medpace Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 440.65.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Medpace Holdings Inc's Score

Industry at a Glance

Industry Ranking
44 / 384
Overall Ranking
147 / 4494
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Medpace Holdings Inc Highlights

StrengthsRisks
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.17% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.53B.
Undervalued
The company’s latest PE is 26.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.60M shares, decreasing 9.58% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 17.24K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.05.

Analyst Rating

Based on 14 analysts
Hold
Current Rating
440.649
Target Price
+3.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Medpace Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Medpace Holdings Inc Info

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Ticker SymbolMEDP
CompanyMedpace Holdings Inc
CEOTroendle (August J)
Websitehttps://investor.medpace.com/
KeyAI